AbCellera is a privately held company located in Vancouver, Canada, that is a world-leading innovator in antibody discovery for therapeutics, and immune profiling for vaccine research. AbCellera works in partnerships with researchers from academia, non-profit organizations, and industry to enable and accelerate the development of new antibody therapies and new vaccines.

Our single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation.

Ultra-deep screening of single B cells allows us unprecedented access to natural immune responses, and enables rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans. The combination of speed, screening depth, and greater specificity translates to successful discovery against difficult targets such as membrane proteins, GPCRs and ion channels.